SCHEMBL1506083

SCHEMBL1506083

COCCOc1ncc(Cl)cc1C(=O)NC1N=C(c2c(Cl)cc(Cl)cc2CN2CCOCC2)c2ccccc2NC1=O

nearest known ligand 0.58

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CBLB Q13191 19/20 0.58
CCKAR P32238 3/20 0.49
CCKBR P32239 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1505988 0.95 CBLB (0.56) CBLBCCKARCCKBR
SCHEMBL1505971 0.90 CBLB (0.58) CBLBCCKARCCKBR
SCHEMBL1505876 0.87 CBLB (0.56) CBLBCCKARCCKBR
SCHEMBL6518719 0.87 CCKBR (0.57) CCKARCCKBR
SCHEMBL1505980 0.81 CCKBR (0.58) CCKARCCKBR
SCHEMBL1505952 0.81 CCKBR (0.58) CCKARCCKBR
SCHEMBL6521775 0.81 CCKBR (0.54) CCKARCCKBR
SCHEMBL1505951 0.81 CCKBR (0.58) CCKARCCKBR
SCHEMBL1506120 0.80 CCKBR (0.54) CCKARCCKBR
SCHEMBL1506186 0.79 CCKBR (0.57) CCKARCCKBR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011027156-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION ARROW THERAPEUTICS LIMITED (GB) 2011-03-10 WO disclosed
WO-2011027156-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION ARROW THERAPEUTICS LIMITED (GB) 2011-03-10 WO disclosed
US-20110059043-A1 CHEMICAL COMPOUNDS ARROW THERAPEUTICS LIMITED (GB) 2011-03-10 US disclosed
US-20110059043-A1 CHEMICAL COMPOUNDS ARROW THERAPEUTICS LIMITED (GB) 2011-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059043-A1 CHEMICAL COMPOUNDS CYP2E1, CNR1, CYP3A5 CBLB 2079/4885CCKAR 183/4885CCKBR 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.